Buprenorphine Market Is Estimated To Witness High Growth Owing To Increasing Approval Of New Products
Buprenorphine Market |
Market Overview:
The buprenorphine market includes drugs used for the
treatment of opioid addiction and pain management. Buprenorphine is a partial
opioid agonist that helps reducing withdrawal symptoms in patients suffering
from opioid dependency. It provides an effective treatment option due to its
high affinity for opioid receptors and relatively low intrinsic efficacy.
Market key trends:
One of the major trends in The
Buprenorphine Market Demand is increasing approval of new products. In
April 2023, Braeburn received FDA approval for weekly buprenorphine depot
injection (CAM2038) for the treatment of moderate to severe opioid use
disorder. The drug delivers continuous plasma levels of buprenorphine over a
week with a single subcutaneous injection. Such new product approvals are
expected to fuel the market growth during the forecast period by providing
improved treatment options.
Porter’s Analysis
Threat of new entrants: Low barrier for new players to enter the market due
to moderate capital requirements. However, established brands, patents and
economies of scale advantage enjoyed by existing players pose entry barriers.
Bargaining power of buyers: Buyers have moderate bargaining power due to
availability of substitutes and differentiated products offered by suppliers.
Bargaining power of suppliers: Suppliers have low-to-moderate bargaining power
due to availability of substitute raw materials and inputs. However, compliance
with stringent regulations provides some bargaining power.
Threat of new substitutes: Threat of substitutes is moderate as alternative
drug therapies are available.
Competitive rivalry: Intense competition due to large number of branded and
generic manufacturers.
SWOT Analysis
Strength: wide applications in treating opioid dependence and chronic pain.
growing awareness and demand.
Weakness: strict regulations for production and distribution. risk of abuse and
addiction.
Opportunity: growing geriatric population prone to chronic diseases. scope in
emerging markets.
Threats: entry of alternative drug therapies. pricing pressure due to low-cost
generic competitors.
Key Takeaways
The global buprenorphine market is expected to witness high growth at a
CAGR of 14% over the forecast period, due to increasing prevalence of opioid
use disorders and chronic pain conditions.
Regionally, North America dominated the global market and is expected to
maintain its lead, owing to rising healthcare spending and growing adoption of
buprenorphine therapy. Asia Pacific is anticipated to exhibit fastest growth
owing to rising geriatric population, growing awareness and improving
healthcare infrastructure in major countries like India and China.
Key players operating in the buprenorphine market are Siegfried, Sanofi,
Johnson Matthey, Mallinckrodt, Noramco, Unichem Laboratories, Arevipharma GmbH,
Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo
Chem, and Faran Shimi Pharmaceutical Co. Major players are focusing on
expanding their manufacturing facilities and product portfolios through
acquisitions and collaborations to strengthen their market position.
Read
More:
https://www.dailyprbulletin.com/rising-addiction-rates-to-drive-the-growth-of-buprenorphine-market/
Comments
Post a Comment